Narcolepsy is a chronic neurological sleep disorder in which the brain has difficulty maintaining stable wakefulness and REM sleep. The central problem is excessive daytime sleepiness (EDS): a daily, hard-to-resist need for sleep or repeated lapses into sleep 1.
That does not mean every person suddenly falls asleep without warning. Some have unintended naps, while others describe a steady pressure to sleep, foggy stretches, or brief losses of alertness during quiet tasks. Symptoms can fluctuate, and a person may appear awake while struggling intensely to stay engaged 12.
Narcolepsy also changes the boundary between wakefulness and REM sleep. Cataplexy, sleep paralysis, vivid sleep-related hallucinations, fragmented nighttime sleep, and automatic behavior can occur, but none of these is required in every person. With the exception of carefully characterized cataplexy in the right diagnostic setting, these experiences are not unique to narcolepsy 1.
The symptom pattern
Excessive daytime sleepiness is the core symptom
EDS is more than ordinary tiredness. It is difficulty sustaining wakefulness during the main waking period, even when someone is trying to remain alert. It may show up as:
- unintended dozing during reading, meetings, classes, conversations, or travel
- a powerful need for a short nap that temporarily restores alertness
- missed information, slowed thinking, memory gaps, or mistakes during sleepy periods
- greater difficulty during monotonous tasks, after meals, or at predictable times of day
- brief lapses that the person may not recognize until someone else points them out
Insufficient sleep can produce a similar experience. So can sleep apnea, circadian misalignment, sedating medicines, substance use, depression, neurological disease, and other medical conditions. Symptoms alone cannot establish narcolepsy, and a sleep test performed after chronic sleep loss can be misleading 3.
Cataplexy is emotion-triggered loss of muscle tone
Cataplexy is a brief episode of involuntary muscle weakness, usually triggered by emotion such as laughter, amusement, surprise, excitement, or anger. Awareness is typically preserved. A partial episode may cause the jaw to sag, eyelids to droop, speech to become unclear, the head to fall forward, or the knees to buckle. A generalized episode can cause a fall. Strength usually returns abruptly after the episode 4.
Cataplexy is not the same as:
- Fainting: syncope usually involves loss of consciousness and may have warning symptoms such as lightheadedness, dimming vision, nausea, or sweating.
- A seizure: seizures may involve altered awareness, sustained stiffening or rhythmic movements, tongue injury, or confusion afterward, depending on the seizure type.
- Ordinary weakness: fatigue or muscle weakness from another condition is usually not a brief, stereotyped, emotion-linked event with preserved awareness and rapid recovery.
These distinctions are not always obvious, especially in children. A clinician may ask a witness for details or review a safely recorded home video. New collapse, loss of consciousness, one-sided weakness, prolonged confusion, or an event unlike the person's established cataplexy needs prompt medical assessment rather than being assumed to be cataplexy 4.
Other REM-boundary symptoms
Sleep paralysis is temporary inability to move when falling asleep or waking. Vivid visual, auditory, or bodily experiences at those transitions are called hypnagogic or hypnopompic hallucinations. They can feel real and frightening, but they arise at the boundary between sleep and wakefulness. Both can occur in people who do not have narcolepsy 1.
Fragmented nighttime sleep can seem contradictory in someone who is very sleepy during the day. Narcolepsy can make sleep and wake states less stable in both directions, leading to repeated awakenings even when total time in bed looks adequate 5.
Automatic behavior means continuing a familiar action during severe sleepiness with reduced awareness and poor recall. The result may be nonsensical writing, misplaced objects, or a routine task completed incorrectly. It is a sign to stop, rest, and avoid hazardous activity, not evidence that someone can safely function while partly asleep 1.
Narcolepsy type 1 and type 2
Both types require persistent EDS and a diagnostic pattern that is not better explained by another sleep disorder, insufficient sleep, circadian timing, a medical or mental disorder, or medication or substance effects. Their evidence pathways differ 62.
| Feature | Narcolepsy type 1 (NT1) | Narcolepsy type 2 (NT2) |
|---|---|---|
| Core clinical symptom | Daily irrepressible need to sleep or daytime sleep lapses for at least 3 months | Daily irrepressible need to sleep or daytime sleep lapses for at least 3 months |
| Cataplexy | May provide the clinical part of a diagnostic route; some people with low CSF orexin do not yet report it | Must be absent |
| Accepted sleep-test route | Typical cataplexy plus either a qualifying MSLT or a REM period within 15 minutes of sleep onset on the preceding overnight PSG | Qualifying MSLT, with an eligible REM period on the preceding PSG able to replace one MSLT REM period |
| MSLT threshold when that route is used | Mean sleep latency of 8 minutes or less and at least 2 sleep-onset REM periods | Mean sleep latency of 8 minutes or less and at least 2 sleep-onset REM periods |
| CSF orexin route | Low cerebrospinal-fluid hypocretin-1, also called orexin-A, can establish the biological criterion | Orexin is not low if measured |
| Exclusions | Findings must not be better explained by another cause | Findings must not be better explained by another cause, making test preparation and the differential diagnosis especially important |
The ICSD-3-TR changed one important NT1 route: typical cataplexy plus a sleep-onset REM period on the overnight polysomnogram can meet the objective component without a qualifying MSLT. Low CSF hypocretin-1 is a separate route. The criterion is 110 pg/mL or less when measured by radioimmunoassay using the Stanford reference sample, or less than one-third of the mean value in healthy people using the same standardized assay 6.
NT2 is less biologically defined. Its MSLT pattern is less stable when testing is repeated than the NT1 pattern, and some people are later reclassified. If clear cataplexy develops or CSF orexin is found to be low, the diagnosis changes to NT1. If repeat testing no longer supports narcolepsy, the clinician should reconsider sleep sufficiency, circadian timing, medicines, substances, and other central hypersomnolence disorders rather than treating the original label as permanent proof 72.
What causes narcolepsy?
In NT1, the strongest model is an immune-mediated loss of neurons that produce orexin, a signaling system that helps stabilize wakefulness and REM sleep. The evidence supports an immune contribution, but the exact trigger and pathway are usually unknown in an individual person. It is more accurate to say NT1 is likely immune-mediated than to claim that a specific infection, stressful event, toxin, or lifestyle choice caused it 1.
The HLA-DQB1*06:02 variant is strongly associated with NT1, but it is a susceptibility marker, not a diagnosis. Many people who carry it never develop narcolepsy, and a negative result does not exclude every case. HLA testing therefore has limited value by itself 12.
The biology of NT2 is less certain and probably heterogeneous. Some people may have partial orexin-system dysfunction, while others may sit near the current testing boundary between NT2 and another hypersomnolence disorder. Narcolepsy should not be explained as a generic “chemical imbalance,” nor should stress or environmental toxins be presented as established causes 1.
How narcolepsy is diagnosed
A defensible diagnosis starts with the cause of the sleepiness, not with ordering an MSLT in isolation.
1. Describe sleepiness and possible cataplexy precisely
A sleep clinician asks when EDS began, how often sleep lapses occur, whether naps are refreshing, and how symptoms affect school, work, driving, and daily safety. A detailed account of any collapse or muscle weakness matters. The clinician also reviews nighttime sleep, shift work, other sleep disorders, mental and neurological symptoms, medical conditions, and every prescribed, over-the-counter, and nonprescribed substance.
2. Document adequate sleep and a stable schedule
Before a diagnostic Multiple Sleep Latency Test (MSLT), the AASM recommends documenting adequate sleep with a sleep diary for two weeks and actigraphy when available. Shift work, delayed sleep timing, jet lag, or chronic sleep restriction can make someone fall asleep quickly or enter REM early for reasons other than narcolepsy 3.
Existing sleep disorders should be effectively treated before testing. For example, if obstructive sleep apnea is being treated with PAP, the clinician should review effectiveness and adherence and decide whether the testing conditions reflect stable treatment 3.
3. Plan medicines, substances, and caffeine with the clinician
Alerting, sedating, and REM-modulating drugs can change MSLT results. Abruptly stopping an antidepressant can also produce REM rebound and create extra sleep-onset REM periods. AASM guidance generally uses a washout of at least two weeks for interfering agents, but the actual plan depends on half-life, withdrawal risk, mental health, and safety. Some medicines require longer; others should not be stopped. The prescriber and sleep clinician should agree on the plan. Do not stop a stimulant, antidepressant, sedative, or other medicine on your own 3.
Caffeine, nicotine, alcohol, cannabis, and other substances also require a documented plan. The laboratory may use a drug screen when an unreported or accidental exposure could invalidate the result.
4. Perform overnight polysomnography followed by the MSLT
The diagnostic MSLT follows an attended overnight polysomnogram (PSG). The PSG checks sleep duration and timing and looks for sleep apnea, limb movements, or another explanation. AASM recommends at least seven hours in bed with at least six hours of recorded sleep, aligned with the person's major sleep period. The MSLT then provides five daytime nap opportunities under standardized conditions and measures average sleep latency and sleep-onset REM periods 3.
A short latency or two REM-onset periods is not meaningful without this preparation. The sleep specialist interprets the study alongside the history, sleep records, PSG, treatment data, and medication and substance plan.
5. Use CSF orexin or genetic testing selectively
Measuring CSF hypocretin-1 requires a lumbar puncture and a validated assay. It can be useful when NT1 remains strongly suspected but cataplexy is unclear, an MSLT cannot be interpreted, or a direct biological result would change care. It is not a routine screening test for all daytime sleepiness 62.
HLA testing cannot confirm or rule out narcolepsy on its own. It may occasionally help a specialist decide whether CSF testing is worth pursuing, but it should not replace the clinical history and validated diagnostic criteria 1.
Treatment is matched to the symptom
There is no current cure and no medicine guarantees full alertness. Treatment aims to reduce specific symptoms, improve function, and lower risk while accounting for age, pregnancy plans, cardiovascular and mental health, other sleep disorders, interactions, access, and personal priorities.
Excessive daytime sleepiness
For adults with narcolepsy, the AASM strongly recommends modafinil, pitolisant, sodium oxybate, and solriamfetol as supported options. Armodafinil, dextroamphetamine, and methylphenidate have conditional recommendations. “Strong” describes the guideline recommendation, not a promise that a drug is best for every person. The list is alphabetical, not a treatment ranking 5.
These drugs work differently. Modafinil and armodafinil are wake-promoting agents. Solriamfetol increases dopamine and norepinephrine signaling. Pitolisant acts through the histamine H3 receptor. Oxybates are taken at night and can improve daytime sleepiness as well as cataplexy in suitable patients. Traditional stimulants remain useful for some people, but narcolepsy treatment is not simply “take a stimulant” 5.
Cataplexy and other REM-related symptoms
A drug chosen for sleepiness may not adequately control cataplexy. European guideline recommendations support oxybate medicines and selected antidepressants for adult cataplexy, with pitolisant another option. Antidepressants used for cataplexy or REM-boundary symptoms are often off-label, depending on the drug and country. They should be started, changed, and stopped through a clinician because abrupt withdrawal can worsen cataplexy 8.
The treatment target should be explicit: fewer sleep lapses, fewer injuries from cataplexy, less fragmented night sleep, or less distress from paralysis and hallucinations. Follow-up should ask whether that target improved and whether adverse effects created a new problem.
Planned naps and practical scheduling
Brief, scheduled naps can improve alertness for some people and are strongly supported in European guidance as part of EDS management. They are usually an addition to treatment, not a substitute for effective medication when sleepiness remains unsafe. The useful timing and length vary, so the plan should be based on when sleepiness actually peaks rather than a generic sleep-hygiene checklist 89.
A consistent main sleep period can reduce the extra burden of sleep deprivation, but it does not correct the underlying narcolepsy. Alcohol and sedating drugs can worsen alertness or interact dangerously with treatment. Other sleep disorders still need their own management.
Medication safety requires a drug-specific review
Narcolepsy medicines do not share one risk profile. Before starting or changing treatment, review cardiovascular history, mood symptoms, other prescriptions and supplements, contraception, pregnancy plans, alcohol and substance use, and the current label in the country where the drug is prescribed.
Important examples from current U.S. labels include:
- Modafinil: rare serious rash and hypersensitivity require urgent attention. It can reduce the effectiveness of steroidal contraceptives during treatment and for one month after stopping 10.
- Solriamfetol: it can raise blood pressure and heart rate, so hypertension should be controlled and monitored. It must not be combined with an MAO inhibitor or used within 14 days after one 11.
- Pitolisant: it can prolong the QT interval and has important interaction checks. It can reduce hormonal contraceptive effectiveness during treatment and for at least 21 days afterward 12.
- Oxybates: these are central nervous system depressants with boxed warnings for respiratory depression and abuse or misuse. They must not be combined with alcohol or sedative-hypnotics and require careful review of other CNS depressants. U.S. distribution uses a restricted safety program 13.
This is not a complete interaction list. A pharmacist or prescriber should check the exact product, dose, kidney and liver function, and all concurrent drugs.
Pregnancy and breastfeeding
Pregnancy planning is a medicine-by-medicine risk-benefit decision, not a rule that all narcolepsy medicines are automatically continued or automatically stopped. Untreated severe sleepiness or cataplexy can also create injury, driving, and work risks.
Review the plan with the sleep clinician and an obstetric clinician before conception when possible. Include the current pregnancy and lactation data for each medicine, contraceptive interactions, expected symptom changes if treatment is reduced, and safer transportation or work arrangements. Do not stop prescribed treatment abruptly. Modafinil labeling includes fetal-risk warnings based on animal data and a steroidal-contraceptive interaction; pitolisant has a different contraceptive-interaction period 1012.
Children and adolescents
Pediatric narcolepsy needs specialist care rather than a scaled-down adult plan. Cataplexy can look different in children, with facial slackness or unusual facial and tongue movements, and sleepiness may be mistaken for inattention, irritability, or poor motivation 49.
Medication approvals vary by age, formulation, country, and indication and can change over time. The clinician should use the current local label, monitor growth, cardiovascular and mental health, and coordinate a school safety and accommodation plan. Scheduled naps, flexibility for symptom flares, and a place to rest may be useful, but they should not lower academic expectations or replace effective treatment 58.
Daily safety and accommodations
Driving
A diagnosis alone does not determine whether a person can drive safely, and taking medicine does not guarantee safe alertness. Local licensing and reporting rules differ. Discuss actual unintended dozing, near misses, lane drifting, missed exits, commute timing, and response to treatment with the treating clinician.
Do not begin or continue driving when you feel unable to stay awake. If sleepiness develops on the road, pull over in a safe place rather than trying to push through. Caffeine may provide brief help but does not reliably prevent microsleeps. Arrange another driver or alternative transport when symptoms are not controlled 14.
Work and school
Useful adjustments are tied to the person's pattern and responsibilities. Examples include:
- a private place and defined time for a planned nap
- a later start or modified schedule when clinically appropriate
- brief alertness breaks during long, quiet tasks
- flexible timing for appointments or medication changes
- written instructions or recorded lectures when a lapse could cause missed information
- moving safety-critical tasks away from the person's sleepiest period
In the United States, a person whose condition qualifies as a disability may request a reasonable workplace accommodation; options and legal standards differ elsewhere. The request is stronger when a clinician documents the functional limitation and the specific adjustment needed 15.
Swimming, heights, cooking, and machinery
If sleepiness or cataplexy is not reliably controlled, avoid swimming alone, climbing ladders, working at an unprotected height, operating dangerous machinery, or using an open flame or sharp tool during a high-risk period. A buddy, lifeguard, seated preparation area, induction appliance, task guard, or schedule change can reduce risk. The plan should reflect the person's actual symptoms instead of assuming everyone with narcolepsy has the same restrictions.
A cataplexy support plan
A trusted person can learn what a typical episode looks like and how to protect the person from a fall without restraining them. Support the head if needed, remove nearby hazards, and allow the episode to pass. A familiar, brief episode with preserved awareness can follow the established support plan. An event that is new, clearly different, involves loss of consciousness, or is followed by prolonged confusion should receive prompt medical assessment rather than be assumed to be cataplexy 4.
Mood, relationships, and follow-up
Narcolepsy can affect concentration, confidence, work, education, caregiving, and social life. Being misread as lazy or disengaged adds another burden. Follow-up should include mood, anxiety, isolation, weight change, substance use, and the effect of symptoms on relationships, not only a sleepiness score 19.
A useful review visit asks:
- Which symptom is still causing the most harm?
- Are there unintended naps, cataplexy-related falls, or driving near misses?
- Is the medicine helping at the time of day it is needed?
- Are nighttime sleep, blood pressure, mood, appetite, or weight changing?
- Have contraception, pregnancy plans, other medicines, or substance use changed?
- Does the school, work, or household safety plan still fit?
Good narcolepsy care is not built around one dramatic symptom or one test result. It combines a well-prepared diagnosis, treatment aimed at the person's actual symptom burden, ongoing safety review, and practical support that lets the person participate in daily life.
